ArticleAntimicrobial agents and chemotherapy2018
Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus onFrontiers in microbiology · 2025Pooled it
- A Narrative Review of Local Therapies in Hidradenitis Suppurativa: Treatment Landscape and Current Issues.Dermatology and therapy · 2026Review
- Rational Targeting and gRNA Design for Enhancing Quorum Quenching inComputational and structural biotechnology journal · 2026Article
- Article
- Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.Microbial biotechnology · 2025Review
- Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants.Antibiotics (Basel, Switzerland) · 2023Article
- Combatting persister cells: The daunting task in post-antibiotics era.Cell insight · 2023Review
- Daunorubicin resensitizes Gram-negative superbugs to the last-line antibiotics and prevents the transmission of antibiotic resistance.iScience · 2023Article
- Exploring Oceans for Curative Compounds: Potential New Antimicrobial and Anti-Virulence Molecules againstMarine drugs · 2022Review
- Recent Advances in the Control of Clinically Important Biofilms.International journal of molecular sciences · 2022Review
- Triclosan: A Small Molecule with Controversial Roles.Antibiotics (Basel, Switzerland) · 2022Review
- Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic FibrosisInternational journal of molecular sciences · 2022Article
- Article
- Review
- Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity AgainstFrontiers in microbiology · 2021Article
- An Overview of Biological and Computational Methods for Designing Mechanism-Informed Anti-biofilm Agents.Frontiers in microbiology · 2021Review
- Triclosan depletes the membrane potential in Pseudomonas aeruginosa biofilms inhibiting aminoglycoside induced adaptive resistance.PLoS pathogens · 2020Article
- Article
- Multitarget Approaches against Multiresistant Superbugs.ACS infectious diseases · 2020Review
- Identification of Drug Resistance Determinants in a Clinical Isolate of Pseudomonas aeruginosa by High-Density Transposon Mutagenesis.Antimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
One of the most important clinical obstacles in cystic fibrosis (CF) treatment is antibiotic treatment failure due to biofilms produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.